SGMO - Sangamo Therapeutics 10% owner Biogen discloses sale of 6M shares
2023-09-29 13:22:44 ET
More on Sangamo Therapeutics
- Sangamo Therapeutics: Recent Updates Bolster My Long-Term Conviction
- Sangamo Therapeutics GAAP EPS of -$0.66 misses by $0.32, revenue of $6.84M misses by $8.49M
- Sangamo gains on option and license agreement with Chroma
- Seeking Alpha’s Quant Rating on Sangamo Therapeutics
For further details see:
Sangamo Therapeutics 10% owner Biogen discloses sale of 6M shares